MTDH and prostate carcinoma: Although there are not a lot of clinicopathologic studies in prostate cancer, the two studies described above are in-depth and comprehensive demonstrating utility of AEG-1 as a useful diagnostic/prognostic marker for metastatic and recurrent disease with poor survival.